---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-178504"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:47:08.739641+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Taysha Q2 net loss $26.9M; TSHA-102 pivotal trial site activation begun, enrollment Q4 2025

## Summary
- Cash $312.8M after $230M follow-on offering; runway extended into 2028.
- Net loss $26.9M ($0.09/share) vs $20.9M ($0.09) in Q2 2024.
- REVEAL pivotal trial site activation commenced; FDA and Health Canada feedback received.
- 100% response rate on primary endpoint in Part A; no treatment-related SAEs or DLTs in 12 patients.
- New supplemental clinical data from Part A expected in Q4 2025.

## SEC filing metadata
- accession: 0001193125-25-178504
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/0001193125-25-178504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/d51118d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-178504
- JSON: https://secwatch.observer/filing/0001193125-25-178504.json
- Plain text: https://secwatch.observer/filing/0001193125-25-178504.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.